Skip to content

U.S. senator slams Canada’s drug prices

An American legislator called Canada “parasitic” on Wednesday for siphoning U.S. dollars to Canada with low prescription drug prices while his country does “all the innovation.”

An American legislator called Canada “parasitic” on Wednesday for siphoning U.S. dollars to Canada with low prescription drug prices while his country does “all the innovation.”

Canada benefits financially from America’s role as a world leader in medical advances, Republican Senator Bob Corker charged in an exchange with a Liberal MP as she testified before a U.S. Senate committee.

“One of the things that has troubled me greatly about our system is the fact that we pay more for pharmaceuticals and devices than other countries, and yet it’s not really our country so much that’s the problem, it’s the parasitic relationship that Canada and France and other countries have towards us,” the Tennessee lawmaker told Carolyn Bennett.

“Meaning that you set prices and unfortunately all the innovation, all the technological breakthroughs, just about, take place in our country .… You benefit from us, and we pay for that, and I resent that.”

Bennett, a family doctor and one-time minister of state for public health, was one of five people testifying before the Senate special committee on aging. The panel, chaired by Democratic Sen. Herb Kohl and including newly minted Sen. Al Franken, was examining how successful health-care systems keep their costs low while maintaining quality care.

She seemed puzzled by Corker’s remarks, reminding him that drug pricing was a global concern, not part of a plot by Canada.

“It’s the drug companies, sir, and they’re multinational — it’s nothing about the United States of America,” she told him.

Their debate comes as U.S. Democratic senator Byron Dorgan from North Dakota is preparing to make a legislative push in the days to come that would legally allow Americans to buy cheaper Canadian drugs.

Dorgan will introduce an amendment to the health-care reform legislation soon.